Back to Archived News
Cardima Announces Patent for INTELLITEMP® Energy Management Device
Thursday, October 11, 2007
Cardima, Inc. (OTCBB: CADM), developer of the REVELATION® Tx, REVELATION® T-Flex ablation microcatheters and INTELLITEMP® Energy Management Device, announces today that it received a new patent from the U.S. Patent and Trademark Office (U.S. Patent No. 7,252,664) for the Company's commercially available product, the INTELLITEMP® Energy Management Device. This device is used to control the delivery of radio-frequency (RF) energy during ablation procedures in the electro-physiology and surgical markets. The feedback system incorporates both temperature and impedance from Cardima's full line of ablation microcatheters and surgical probes. This patent reinforces the uniqueness of the INTELLITEMP's modular architecture that controls RF energy delivery to any combination of up to 8 electrodes simultaneously along a linear ablation catheter or surgical probe. In comparison to standard "drag and burn" ablation technologies, simultaneous ablation through multiple electrodes of a Cardima linear ablation catheter or surgical probe controlled by the INTELLITEMP shortens procedure time. Furthermore, this process safely creates clean lesions that have penetrating depth, without gaps along the linear trajectory. The INTELLITEMP is marketed in the U.S.A. as part of the Cardima Surgical Ablation System, and CE Marked in the EU for both surgical and cardiac electro-physiology ablation applications.
Eric Chan, Ph.D., Chief Technology Officer and co-inventor on the patent, said, "Improved lesion creation effectiveness as well as reduced procedure time has been demonstrated in over a hundred ablation cases in the USA and UK, by using the INTELLITEMP® in conjunction with the Company's surgical ablation probes, as well as the REVELATION® Helix STX and REVELATION® T-Flex ablation catheters. This U.S. patent issuance that claims the INTELLITEMP's unique modular architecture is an important milestone in Cardima's intellectual property portfolio."
Cardima, Inc. has developed the PATHFINDER® series of diagnostic catheters, the REVELATION® series ablation catheters, the INTELLITEMP® Energy Management Device, and the Surgical Ablation System (SAS). The REVELATION series with the INTELLITEMP Energy Management Device was developed for the treatment of atrial fibrillation (AF) and received CE mark approval in Europe. The PATHFINDER series diagnostic catheters and the SAS including the INTELLITEMP has received U.S. FDA 510(k) clearance.
For more information, please visit the Company's website at http://www.cardima.com.
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those expressed in or implied by such forward-looking statements. Potential risks and uncertainties include: the uncertainties associated with the prospects for FDA approval of any new devices; the prospect for any future clinical trials or regulatory activities; the risk that the Company will not be able to raise additional capital in the immediate term as needed to continue operations and the risk that we will be unable to secure a strategic transaction involving the Surgical Ablation System. Additional risks and uncertainties are set forth in the Company's Annual Report on Form 10-KSB for the year ended December 31, 2006, the Company's Quarterly Report on Form 10-QSB for the second quarter ended June 30, 2007, and in the Company's subsequent SEC filings. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events or changes in the Company's plans or expectations.
Back to Archived News